Fennec Pharmaceuticals Inc.
General ticker "FENC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $271.9M (TTM average)
Fennec Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 52.4%.
Estimated limits based on current volatility of 2.6%: low 9.95$, high 10.49$
Factors to consider:
- Total employees count: 35 (+9.4%) as of 2025
- Top business risk factors: History of losses, Financing risks, Clinical trial delays, Regulatory and compliance, Marketing failure
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.71$, 12.97$]
- 2026-12-31 to 2027-12-31 estimated range: [7.43$, 14.07$]
Financial Metrics affecting the FENC estimates:
- Positive: with PPE of -22.8 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Positive: -13.52 < Operating profit margin, % of -12.34
- Positive: 49.86 < Shareholder equity ratio, % of 50.28 <= 58.56
- Positive: Interest expense per share per price, % of 0.94 <= 1.42
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: -0.14 < Investing cash flow per share per price, % of 0
- Negative: 0.41 < Inventory ratio change, % of 0.68
Short-term FENC quotes
Long-term FENC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $21.25MM | $47.54MM | $44.64MM |
| Operating Expenses | $34.02MM | $44.97MM | $50.92MM |
| Operating Income | $-12.77MM | $2.57MM | $-6.28MM |
| Non-Operating Income | $-3.20MM | $-2.64MM | $-3.35MM |
| Interest Expense | $3.39MM | $4.07MM | $2.08MM |
| R&D Expense | $0.06MM | $0.31MM | $0.25MM |
| Income(Loss) | $-15.97MM | $-0.07MM | $-9.63MM |
| Taxes | $0.00MM | $0.36MM | $0.11MM |
| Net Income(Loss)* | $-15.97MM | $-0.44MM | $-9.74MM |
| Stockholders Equity | $-11.62MM | $-5.87MM | $35.47MM |
| Inventory | $2.16MM | $1.06MM | $1.56MM |
| Assets | $26.86MM | $44.95MM | $70.55MM |
| Operating Cash Flow | $-17.14MM | $26.98MM | $-12.47MM |
| Financing Cash Flow | $6.64MM | $-13.62MM | $22.63MM |
| Earnings Per Share** | $-0.60 | $-0.02 | $-0.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.